ACET Stock Summary and Trading Ideas (Adicet Bio | NASDAQ:ACET)

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Adicet Bio trades on the NASDAQ stock market under the symbol ACET.

As of March 27, 2025, ACET stock price declined to $0.85 with 267,886 million shares trading.

ACET has a beta of 1.60, meaning it tends to be more sensitive to market movements. ACET has a correlation of 0.10 to the broad based SPY ETF.

ACET has a market cap of $70.28 million. This is considered a Micro Cap stock.

In the last 3 years, ACET traded as high as $21.87 and as low as $.74.

The top ETF exchange traded funds that ACET belongs to (by Net Assets): VTI, VXF, FESM, IWC, CNCR.

ACET has underperformed the market in the last year with a return of -62.1%, while the SPY ETF gained +11.0%. In the last 3 month period, ACET fell short of the market, returning -11.5%, while SPY returned -5.2%. However, in the most recent 2 weeks ACET has outperformed the stock market by returning +7.1%, while SPY returned +2.0%.

ACET support price is $.85 and resistance is $.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACET shares will trade within this expected range on the day.